TMC LIFE SCIENCES BERHAD

Malaysia | 0101.KL | Main

By Sustify.world AI model | 2025-05-24
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company's reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation programmes; and offers fertility consultancy services; laboratory and embryology; traditional and complementary; pharmacy services and products; and management support and multi-disciplinary tertiary care services. Further, it operates a women's clinic and fertility centers, as well as provides related services; develops, markets, and manages healthcare programs; and operates pharmacy store. Additionally, the company engages in the research and development activities; and property investment activities. TMC Life Sciences Berhad was founded in 1994 and is based in Petaling Jaya, Malaysia. The company is a subsidiary of Sasteria (M) Pte. Ltd.

Reference

Report Year: 2024
Source Files: Annual_Report_2024-Part_1.pdf

Sustainability Committee

Sustainability Management Committee (Members Unknown) 🟢

  • Oversees initiatives 🟢
  • Task force actions 🟢

Reporting

GRI, TCFD, SASB, IFRS S1, IFRS S2, Integrated Report 🟢

GHG Accounting

TMC Life Sciences Berhad demonstrates a structured approach to GHG accounting with third-party verification for Scope 1 and 2 emissions, reporting 690.33 tCO₂e and 12506.00 tCO₂e respectively in FY2024. Scope 3 emissions (8732.00 tCO₂e) have been expanded, reflecting improved data consolidation. The use of IPCC AR6 and DEFRA factors ensures accuracy, aligned with the GHG Protocol. However, a base year is yet to be established (targeted for FY2025), limiting trend analysis. Carbon intensity metrics (0.21 tCO₂e/m² GFA) provide operational insights. A key improvement area is setting clearer reduction targets to support the Net Zero by 2050 goal, alongside more comprehensive Scope 3 coverage.

Emissions

Scope Value Note
Scope1 690.33 tCO₂e 🟢 Verified by third party 🟢
Scope2 12506.00 tCO₂e 🟢 Verified by third party 🟢
Scope3 8732.00 tCO₂e 🟢 Includes business travel and employee commuting, expanded measurement in FY2024
Biogenic emissions Not applicable → No biomass or biofuel usage reported.

Other Details

  • Base year: Not established (Target FY2025)
  • Boundary inventory: Operational control approach covering Thomson Hospital Kota Damansara, TMC Fertility Centres, Thomson TCM, TMC Care Pharmacy, and corporate HQ
  • Gwp basis: IPCC AR6, DEFRA (2023)
  • Standard: GHG Protocol
  • Third party verification: Verified (Scope 1 and 2 by Ernst & Young Consulting Sdn. Bhd.)
  • Carbon intensity: 0.21 tCO₂e/m² GFA, 0.06 tCO₂e/RM'000 revenue, verified 🟢

Efforts

  • Solar energy: 500 MWh 🟢
  • Recycled 28.44 tonnes 🟢
  • Solar panels installed 🌞
  • Rainwater harvesting 🌧️

Social Highlights

  • RM89,549 invested, 2,943 beneficiaries 🥗
  • 33 community projects 🥗
  • 1,161 employees trained 🟢
  • 63% satisfaction rate 🟢
  • 51 students sponsored 🥗

Governance

  • Salary disclosure: Disclosed 🟢
  • Litigation: No litigation ⚠️

Report Quality

Commendable effort by TMC Life Sciences Berhad in producing a detailed sustainability report for FY2024 🟢. The report excels in providing quantifiable metrics such as GHG emissions (21,928 tCO₂e total), waste recycling (28.44 tonnes), and community investment (RM89,549 for 2,943 beneficiaries), supported by third-party verification. Forward-looking commitments like Net Zero by 2050 are noted, adding strategic depth. However, the report has gaps in setting a GHG baseline (targeted for FY2025) and lacks specific interim reduction targets, which limits accountability ⚠️. Some sections include generic statements on sustainability without measurable outcomes. To enhance future reports, the company could incorporate detailed timelines for targets and expand Scope 3 emissions coverage. Overall, it provides a solid foundation but could benefit from more actionable commitments and less reliance on aspirational language.

Tags:

Looking for ESG Strategy & Improvement?

Disclaimer:

This is AI model generated summary based on certain rules set by Sustify.world perspective. If the reader finds the information is incorrect, they can always approach us by sending email admin@sustify.world.

Need Expert help?
Contact us TODAY for sustainability strategy, reporting, and outsourcing services.

Let's talk

Similar Companies

IHH HEALTHCARE BERHAD | Main | 5225.KL
KPJ HEALTHCARE BERHAD | Main | 5878.KL
more -->

We use cookies to enhance your experience on our website. By clicking "Accept", you agree to our use of cookies. Learn more.